Inventiva (IVA) Q2 2026 Earnings Call Transcript
Lanifibranor Phase III results expected Q4 2026, potential FDA submission H1 2027.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
More in Finance & Markets
India rejects Australia's high sugar subsidy claims at WTO
Australia referring to the WTO panel in the India sugar and sugarcane dispute which found in 2021 that India’s sugar support regime was inconsistent with its WTO obligations and subsidies were in…
Dangote says refinery IPO will democratise wealth creation
Dangote said the planned listing is part of a wider strategy to spread ownership of his businesses among the public, allowing investors to earn dividends and benefit from potential increases in the…
Bulk carrier constraints pinch multiple markets
Lead times in the mode have increased from 24-72 hours to seven-10 days, a Q3 Uber Freight report noted.
AFRICA FINANCE IN BRIEF: Botswana second downgrade, Ghana’s new cedi and fresh inflation risks
Here are the stories shaping Africa’s financial markets, economies and businesses this week — from Botswana’s weakening diamond revenues and read more AFRICA FINANCE IN BRIEF: Botswana second…
NNPC’s profit rises 33% to N7.2tn, remits N22.3tn to government
The Nigerian National Petroleum Company Limited has announced a 33% increase in its profit after tax to N7.2tn for the 2025 financial year.
The best early Prime Day deals on Pokémon, including 30th Celebration trading cards for below market price
Early Prime Day Pokémon deals now include a sub-$90 ETB, cheaper booster bundles, Lego, Switch games, and books.